Portfolio Valuation and Ameriabank Acquisition Update
CLINICS & DIAGNOSTICS BUSINESS
OPERATING PERFORMANCE OVERVIEW
&
CLINICS & DIAGNOSTICS
REVENUE DEVELOPMENT¹
+9.7%
☐
KEY DRIVERS
The growth in revenue and EBITDA reflects the
increased demand for non-COVID services and
the expansion of the business.
GEL MILLION
62
20
20
68
18
+27.0%
49
49
41
19
15
5
14
10
4Q22
4Q23
■Clinics Diagnostics - Total
KEY OPERATING HIGHLIGHTS
EBITDA² DEVELOPMENT
NMF
GEORGIA
CAPITAL
+129.9%
13
6
3
0.1
FY22
FY23
4Q22
4Q23
FY22
FY23
4Q22
VS.
■ 4Q23
Change y-o-y
FY22
VS.
■ FY23
Change y-o-y
Clinics
Number of admissions ('000)
Number of registered patients ('000)
Diagnostics
447.1
449.4
+0.5%
1,707.5
1,640.0 -4.0%
615.7
635.8
+3.3%
615.7
635.8
+3.3%
Number of patients served ('000)
Number of total tests performed ('000)
218.2
627.0
201.3
-7.8%
980.7
660.6
+5.4%
2,426.4
778.7
-20.6%
2,470.5
+1.8%
Georgia Capital PLC General comment: The 2023 numbers, as well as the comparative 2022 figures, exclude the performance of the community clinics, which are now presented as part of the hospitals business.
1. Total revenue excludes eliminations between the clinics and diagnostics business lines. 2. Excluding IFRS 16.
69
69View entire presentation